Catalog No.: PC-42035Not For Human Use, Lab Use Only.
eFT508 (Tomivosertib) is a potent, highly selective, reversible, ATP-competitive, and orally bioavailable MNK1 and MNK2 inhibitor with IC50 of 1-2 nM in enzyme assays.
eFT508 (Tomivosertib) is a potent, highly selective, reversible, ATP-competitive, and orally bioavailable MNK1 and MNK2 inhibitor with IC50 of 1-2 nM in enzyme assays.
eFT508 (Tomivosertib) dose-dependently reduces eIF4E phosphorylation at Serine 209 in tumor cell lines with IC50 of 2-16 nM.
eFT508 (Tomivosertib) shows anti-proliferative activity against multiple DLBCL cell lines, decreases the production of pro-inflammatory cytokines including TNFα, IL-6, IL-10 and CXCL10.
eFT508 (Tomivosertib) demonstrates significant anti-tumor activity in human lymphoma xenograft models which harbor activating MyD88 mutations.
